Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Bashan DrorOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:263,960Price:--
-
Oct 19, 2023 (filed on Oct 20, 2023)Insider Name:Bashan DrorOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:16,129Price:$1.41
-
Oct 19, 2023 (filed on Oct 20, 2023)Insider Name:Bashan DrorOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:48,387Price:$1.40
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Boudes Pol FOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Melincoff Gwen AOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Bar-Shalev AmosOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Schwartz AharonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Ben Zvi ShmuelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 14, 2023 (filed on Sep 15, 2023)Insider Name:Forster EliotOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,715Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Bashan DrorOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800,000Price:--
Filings by filing date
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Bashan DrorOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:263,960Price:--
-
Oct 19, 2023 (filed on Oct 20, 2023)Insider Name:Bashan DrorOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:16,129Price:$1.41
-
Oct 19, 2023 (filed on Oct 20, 2023)Insider Name:Bashan DrorOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:48,387Price:$1.40
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Boudes Pol FOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Melincoff Gwen AOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Bar-Shalev AmosOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Schwartz AharonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 29, 2023 (filed on Oct 03, 2023)Insider Name:Ben Zvi ShmuelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:61,676Price:--
-
Sep 14, 2023 (filed on Sep 15, 2023)Insider Name:Forster EliotOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,715Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Bashan DrorOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2 University Plaza, Suite 100 HACKENSACK NJ 07601 |
Tel: | 1-646-8891200 |
Website: | https://protalix.com |
IR: | See website |
Key People | ||
Dror Bashan President, Chief Executive Officer, Director | Eyal Rubin Chief Financial Officer, Senior Vice President, Treasurer, Secretary | Yaron Naos Senior Vice President - Operations | Yael Hayon Vice President - Research & Development |
Business Overview |
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. |
Financial Overview |
For the fiscal year ended 31 December 2023, Protalix Biotherapeutics Inc revenues increased 37% to $65.5M. Net income totaled $8.3M vs. loss of $14.9M. Revenues reflect Revenues from selling Goods increase of 60% to $40.4M, Revenues from License and R&D Services increase of 12% to $25.1M. Net Income reflects RESEARCH AND DEVELOPMENT EXPENSES - decrease of 43% to $16.3M (expense), FINANCIAL INCOME increase of 12% to $1.3M (income). |
Employees: | 208 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $80.63M as of Dec 31, 2023 |
Annual revenue (TTM): | $65.49M as of Dec 31, 2023 |
EBITDA (TTM): | $11.65M as of Dec 31, 2023 |
Net annual income (TTM): | $8.31M as of Dec 31, 2023 |
Free cash flow (TTM): | -$2.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 73,052,124 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |